Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its participation in two major investor conferences this November.

The company will participate in a fireside chat at the UBS Global Healthcare Conference on November 13, 2024, at 8:45 a.m. PT at the Terranea Resort, Rancho Palos Verdes. Additionally, they will join the Jefferies London Healthcare Conference on November 19, 2024, at 5:00 p.m. GMT at the Waldorf Hilton, London.

Live webcasts of both presentations will be available on Terns' investor relations website and archived for at least 30 days.

News Market Reaction – TERN

-2.49%

-2.49% Session move

In the trading session that priced this news, TERN declined 2.49%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November.

UBS Global Healthcare Conference
Format: Fireside Chat         
Date and Time: Wednesday, November 13, 2024 at 8:45 a.m. PT
Location: Terranea Resort, Rancho Palos Verdes

Jefferies London Healthcare Conference
Format: Fireside Chat
Date and Time: Tuesday, November 19, 2024 at 5:00 p.m. GMT
Location: Waldorf Hilton, London

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

What investor conferences will Terns Pharmaceuticals (TERN) attend in November 2024?

Terns Pharmaceuticals will participate in two investor conferences: the UBS Global Healthcare Conference on November 13, 2024, and the Jefferies London Healthcare Conference on November 19, 2024.

When and where is Terns Pharmaceuticals (TERN) presenting at the UBS Global Healthcare Conference?

Terns Pharmaceuticals will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 8:45 a.m. PT at the Terranea Resort in Rancho Palos Verdes.

How can investors access Terns Pharmaceuticals (TERN) conference presentations?

Investors can access live webcasts of the presentations through Terns Pharmaceuticals' investor relations website at ir.ternspharma.com. Recordings will be available for at least 30 days after the events.